



## Clinical trial results:

### The use of the non-absorbable marker paromomycin sulfate for the evaluation of the gastrointestinal transit

#### Summary

EudraCT number	2013-000297-30
Trial protocol	BE
Global end of trial date	29 February 2016

#### Results information

Result version number	v1 (current)
This version publication date	09 February 2023
First version publication date	09 February 2023

#### Trial information

##### Trial identification

Sponsor protocol code	DDD13PM
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	Clinical Trial Center UZ Leuven: S55196

Notes:

#### Sponsors

Sponsor organisation name	UZLeuven
Sponsor organisation address	Herestraat 49, Leuven, Belgium, 3000
Public contact	Drug Delivery & Disposition, KU Leuven, 32 16330302, patrick.augustijns@kuleuven.be
Scientific contact	Drug Delivery & Disposition, KU Leuven, 32 16330302, patrick.augustijns@kuleuven.be

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	02 May 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	29 February 2016
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

To evaluate the gastrointestinal transit by the non-absorbable marker paromomycin sulfate

Protection of trial subjects:

Healthy volunteers

xylocaine spray/gel during positioning and removal of nasogastric catheter

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 May 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Belgium: 8
Worldwide total number of subjects	8
EEA total number of subjects	8

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	8
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Main exclusion criteria:

(potential) pregnancy,

frequent exposure to ionizing radiation in the previous year,

history of gastrointestinal pathology and/or illness at the time of the study.

hepatitis B/C- or HIV-infected subjects

### Pre-assignment

Screening details:

Healthy volunteers

### Period 1

Period 1 title	overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	No
------------------------------	----

<b>Arm title</b>	paromomycin during MMC phase I
------------------	--------------------------------

Arm description:

paromomycin 250mg during MMC phase I

Arm type	Experimental
Investigational medicinal product name	paromomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral administration of one tablet of Gabbrolal (250 mg paromomycin) with 240 mL of tap water during MMC phase I (i.e. absence of contractions).

<b>Arm title</b>	paromomycin during MMC phase II
------------------	---------------------------------

Arm description:

paromomycin 250mg during MMC phase II

Arm type	Experimental
Investigational medicinal product name	paromomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral administration of one tablet of Gabbrolal (250 mg paromomycin) with 240 mL of tap water during MMC phase II (i.e. period of gastric contractions).

<b>Number of subjects in period 1</b>	paromomycin during MMC phase I	paromomycin during MMC phase II
Started	8	8
Completed	8	8

## Baseline characteristics

### Reporting groups

Reporting group title	overall study
-----------------------	---------------

Reporting group description: -

Reporting group values	overall study	Total	
Number of subjects	8	8	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
median	24		
full range (min-max)	20 to 26	-	
Gender categorical			
Units: Subjects			
Female	2	2	
Male	6	6	

## End points

### End points reporting groups

Reporting group title	paromomycin during MMC phase I
Reporting group description: paromomycin 250mg during MMC phase I	
Reporting group title	paromomycin during MMC phase II
Reporting group description: paromomycin 250mg during MMC phase II	

### Primary: not applicable

End point title	not applicable <sup>[1]</sup>
End point description: Since we only conduct exploratory studies in a limited number of volunteers, statistical hypothesis testing is not applicable	
End point type	Primary
End point timeframe: not applicable	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Since we only conduct exploratory studies in a limited number of volunteers, statistical hypothesis testing is not applicable

End point values	paromomycin during MMC phase I	paromomycin during MMC phase II		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	8		
Units: NA	8	8		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

---

### Adverse events information<sup>[1]</sup>

---

Timeframe for reporting adverse events:

For each individual, corresponds to timeframe of study participation (from signing of informed consent until last visit).

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	23

Frequency threshold for reporting non-serious adverse events: 5 %

---

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: there were no adverse events during the trial

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Since we only conduct exploratory studies in a limited number of volunteers, statistical hypothesis testing is not applicable
---

Notes:

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/27865990>

<http://www.ncbi.nlm.nih.gov/pubmed/25064697>